Amneal Pharmaceuticals Statistics
Total Valuation
AMRX has a market cap or net worth of $5.43 billion. The enterprise value is $7.93 billion.
| Market Cap | 5.43B |
| Enterprise Value | 7.93B |
Important Dates
The next confirmed earnings date is Thursday, July 30, 2026, before market open.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AMRX has 319.02 million shares outstanding. The number of shares has increased by 5.20% in one year.
| Current Share Class | 319.02M |
| Shares Outstanding | 319.02M |
| Shares Change (YoY) | +5.20% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 44.05% |
| Owned by Institutions (%) | 51.64% |
| Float | 178.41M |
Valuation Ratios
The trailing PE ratio is 45.86 and the forward PE ratio is 16.97.
| PE Ratio | 45.86 |
| Forward PE | 16.97 |
| PS Ratio | 1.78 |
| Forward PS | 1.72 |
| PB Ratio | 135.94 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 26.20 |
| P/OCF Ratio | 17.75 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.87, with an EV/FCF ratio of 38.24.
| EV / Earnings | 64.90 |
| EV / Sales | 2.60 |
| EV / EBITDA | 11.87 |
| EV / EBIT | 17.19 |
| EV / FCF | 38.24 |
Financial Position
The company has a current ratio of 2.47, with a Debt / Equity ratio of 67.51.
| Current Ratio | 2.47 |
| Quick Ratio | 1.52 |
| Debt / Equity | 67.51 |
| Debt / EBITDA | 3.92 |
| Debt / FCF | 13.01 |
| Interest Coverage | 1.94 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 8.35% |
| Return on Invested Capital (ROIC) | 18.60% |
| Return on Capital Employed (ROCE) | 16.40% |
| Weighted Average Cost of Capital (WACC) | 10.40% |
| Revenue Per Employee | $350,099 |
| Profits Per Employee | $14,037 |
| Employee Count | 8,700 |
| Asset Turnover | 0.88 |
| Inventory Turnover | 2.98 |
Taxes
In the past 12 months, AMRX has paid $584,000 in taxes.
| Income Tax | 584,000 |
| Effective Tax Rate | 0.32% |
Stock Price Statistics
The stock price has increased by +106.30% in the last 52 weeks. The beta is 1.26, so AMRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.26 |
| 52-Week Price Change | +106.30% |
| 50-Day Moving Average | 14.42 |
| 200-Day Moving Average | 12.86 |
| Relative Strength Index (RSI) | 69.02 |
| Average Volume (20 Days) | 2,427,344 |
Short Selling Information
The latest short interest is 7.92 million, so 2.48% of the outstanding shares have been sold short.
| Short Interest | 7.92M |
| Short Previous Month | 7.53M |
| Short % of Shares Out | 2.48% |
| Short % of Float | 4.44% |
| Short Ratio (days to cover) | 4.27 |
Income Statement
In the last 12 months, AMRX had revenue of $3.05 billion and earned $122.12 million in profits. Earnings per share was $0.37.
| Revenue | 3.05B |
| Gross Profit | 1.19B |
| Operating Income | 461.17M |
| Pretax Income | 181.90M |
| Net Income | 122.12M |
| EBITDA | 667.78M |
| EBIT | 461.17M |
| Earnings Per Share (EPS) | $0.37 |
Balance Sheet
The company has $200.62 million in cash and $2.70 billion in debt, with a net cash position of -$2.50 billion or -$7.82 per share.
| Cash & Cash Equivalents | 200.62M |
| Total Debt | 2.70B |
| Net Cash | -2.50B |
| Net Cash Per Share | -$7.82 |
| Equity (Book Value) | 39.94M |
| Book Value Per Share | -0.14 |
| Working Capital | 1.07B |
Cash Flow
In the last 12 months, operating cash flow was $305.84 million and capital expenditures -$98.58 million, giving a free cash flow of $207.26 million.
| Operating Cash Flow | 305.84M |
| Capital Expenditures | -98.58M |
| Depreciation & Amortization | 206.60M |
| Net Borrowing | 119.48M |
| Free Cash Flow | 207.26M |
| FCF Per Share | $0.65 |
Margins
Gross margin is 39.16%, with operating and profit margins of 15.14% and 4.01%.
| Gross Margin | 39.16% |
| Operating Margin | 15.14% |
| Pretax Margin | 5.97% |
| Profit Margin | 4.01% |
| EBITDA Margin | 21.92% |
| EBIT Margin | 15.14% |
| FCF Margin | 6.80% |
Dividends & Yields
AMRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.20% |
| Shareholder Yield | -5.20% |
| Earnings Yield | 2.25% |
| FCF Yield | 3.82% |
Analyst Forecast
The average price target for AMRX is $17.25, which is 1.35% higher than the current price. The consensus rating is "Buy".
| Price Target | $17.25 |
| Price Target Difference | 1.35% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 5.87% |
| EPS Growth Forecast (3Y) | 15.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AMRX has an Altman Z-Score of 2.02 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.02 |
| Piotroski F-Score | 7 |